JW Pharmaceutical 001060.KS · KRW

Its shares trade on KRX under the ticker 001060.KS. It has been listed since 14 June 1976. In the fiscal year to 31 December 2025, it reported revenue of ₩775.30bn and net income of ₩61.51bn. At that date it held total assets of ₩605.27bn and shareholders' equity of ₩369.37bn.

JW PHARMACEUTICAL Corp. engages in the development, manufacture, and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The firm also researches and develops anticancer drugs.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Gyeong Ha LeeChairman, since 2018₩849.0m
• Mr. Yeong Seop ShinChief Executive Officer, Director, since 2017
• Mr. Ji Wu ChoiChief Financial Officer, Director
• Mr. Sang Yil LeeAssistant Managing Director
• Mr. Du Yeon ChoAssistant Managing Director, since 2023
• Mr. Ja Eok GuAssistant Managing Director, since 2023
• Mr. Hyeon Seok HanHead of Factory
• Ms. Yun Ju JungAssistant Managing Director, since 2023
• Ms. Gyeong Eun KimAssistant Managing Director
• Mr. Gyeong Taek LeeAssistant Managing Director, since 2023
• Mr. Hoe Ju SonHead of Factory, since 2023
• Mr. Gil Chun YangHead of Factory, since 2023

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.